[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100607507":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":11,"studyPopulation":11,"armGroups":24,"interventions":37,"overallOfficials":46,"centralContacts":50,"locations":56,"responsibleParty":71,"collaborators":11,"id":73,"slug":11,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":11,"eligibilityCriteria":78,"healthyVolunteers":74,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":11,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":11,"overallStatus":59,"whyStopped":11,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Overall Survival (OS)",null,"Up to approximately 3 years",[14,16],{"measure":15,"description":11,"timeFrame":12},"Number of participants with adverse events (AEs)",{"measure":17,"description":11,"timeFrame":12},"Serum Concentrations of ZG006",{"allocation":19,"interventionModel":20,"interventionModelDescription":11,"primaryPurpose":21,"observationalModel":11,"timePerspective":11,"maskingInfo":22},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":23,"maskingDescription":11,"whoMasked":11},"NONE",[25,31],{"label":26,"type":27,"description":28,"interventionNames":29},"ZG006","EXPERIMENTAL","ZG006 10 mg Q2W",[30],"Drug: ZG006",{"label":32,"type":33,"description":34,"interventionNames":35},"Investigator-Selected Chemotherapy","ACTIVE_COMPARATOR","Investigator-selected chemotherapy, such as topotecan.",[36],"Drug: Topotecan",[38,42],{"type":39,"name":26,"description":40,"armGroupLabels":41,"otherNames":11},"DRUG","ZG006 will be administered as an intravenous (IV) infusion.",[26],{"type":39,"name":43,"description":44,"armGroupLabels":45,"otherNames":11},"Topotecan","Topotecan will be administered per local standard of care",[32],[47],{"name":48,"affiliation":5,"role":49},"Jason Wu","STUDY_CHAIR",[51],{"name":52,"role":53,"phone":54,"phoneExt":11,"email":55},"Hewen Yin","CONTACT","+86-0512-57309965","yinhw@zelgen.com",[57],{"facility":58,"status":59,"city":60,"state":61,"zip":62,"country":63,"countryCode":64,"cosmosGeoPoint":65,"geoPoint":70,"contacts":11},"Shanghai Chest Hospital","RECRUITING","Shanghai","Shanghai Municipality","200030","China","CN",{"type":66,"coordinates":67},"Point",[68,69],121.45806,31.22222,{"lat":69,"lon":68},{"type":72,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100607507",false,"NCT07189455","Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer","A Multicenter, Randomized, Controlled, Open-Label Phase III Study Evaluating the Efficacy and Safety of ZG006 for Injection Compared With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer","Inclusion Criteria:\n\n* Fully understand the study and voluntarily sign the informed consent form;\n* Male or female 18\\~75 years of age;\n* Eastern Cooperative Oncology Group(ECOG) Performance Status of 0 or 1;\n* Life expectancy ≥ 3 months;\n* Histologically or cytologically confirmed Small Cell Lung Cancer.\n\nExclusion Criteria:\n\n* Participants were deemed unsuitable for participating in the study by the investigator for any reason.","ALL","18 Years","75 Years",{"count":83,"type":84},420,"ESTIMATED","INTERVENTIONAL",[87],"PHASE3","The main objective is to compare ZG006 with Investigator-Selected Chemotherapy on prolonging overall survival (OS).",[90],"Small-cell Lung Cancer","2025-12-30",{"date":93,"type":94},"2026-01-05","ACTUAL",{"date":96,"type":94},"2025-12-12",{"date":98,"type":84},"2028-12",{"name":5,"class":6},1]